Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)

v3.23.3
Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 29, 2023
Sep. 30, 2023
Jun. 30, 2023
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Agreements                
Long-term royalty and commercial payment receivables   $ 74,696     $ 74,696     $ 63,683
Payments of consideration under RPAs, AAAs and CPPAs         14,650 $ 8,000    
Contingent consideration under RPAs, AAAs and CPPAs   4,000     4,000     75
Receipts under RPAs, AAAs and CPPAs         8,428 $ 3,026    
Short-term royalty and commercial payment receivables   0     0     $ 2,366
Aptevo                
Agreements                
Reduction in long-term royalty receivable balance due to receipt of payment         1,144      
Aptevo | Commercial Payment Purchase Agreement                
Agreements                
Maximum milestone payments entitled to receive $ 5,300              
Long-term royalty and commercial payment receivables 9,700              
Payments of consideration under RPAs, AAAs and CPPAs 9,600              
Contingent consideration under RPAs, AAAs and CPPAs 50 0     0   $ 50  
Commercial payments attributable to net sales threshold $ 500              
Short-term royalty and commercial payment receivables   0     0      
Amount of allowance for credit losses   0     $ 0      
Aptevo | Commercial Payment Purchase Agreement | Minimum                
Agreements                
Receipts under RPAs, AAAs and CPPAs       $ 500        
Medexus | Commercial Payment Purchase Agreement                
Agreements                
Receipts under RPAs, AAAs and CPPAs   $ 600 $ 600